<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021419</url>
  </required_header>
  <id_info>
    <org_study_id>Qehkl</org_study_id>
    <nct_id>NCT05021419</nct_id>
  </id_info>
  <brief_title>Efficacy of a Streamlined Heart Failure Optimization Protocol</brief_title>
  <acronym>SHORT</acronym>
  <official_title>Efficacy of a Streamlined Heart Failure Optimisation pRoTocol for Patients With Severely Impaired Left Ventricular Systolic Function, a Randomised Controlled Trial (SHORT Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SHORT trial compares the current standard optimization protocol to a shortened protocol&#xD;
      in a randomized control trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SHORT trial compares the current standard optimization protocol to a shortened protocol&#xD;
      in a randomized control trial. It assesses whether an accelerated protocol leads to faster&#xD;
      optimization and a greater degree of optimization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to point of optimization</measure>
    <time_frame>Maximum follow-up 6 months</time_frame>
    <description>Do patients on the streamlined protocol reach the point of optimization* earlier?&#xD;
*point of optimization is defined as the point in time at which no medication could be increased further either due to achievement of target doses or limited by symptoms, low heart rate, blood pressure, or raised serum potassium or serum Creatinine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of optimization reached</measure>
    <time_frame>Maximum follow-up 6 months</time_frame>
    <description>1. Do patients on the streamlined protocol reach a greater &quot;degree of optimization&quot; **?&#xD;
** degree of optimization defined as the average percentage of the target doses reached across the four heart failure medication drug groups at the point of optimization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of appointments required</measure>
    <time_frame>Maximum follow-up 6 months</time_frame>
    <description>Do patients on the streamlined protocol require fewer appointments to reach the point of optimization?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Complications</measure>
    <time_frame>Maximum follow-up 6 months</time_frame>
    <description>Is the streamlined protocol as safe as the current best practice protocol? Number of symptomatic hypotension requiring hospitalization and Hyperkalaemia requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-pro BNP</measure>
    <time_frame>6 months</time_frame>
    <description>Do patients on the streamlined protocol have greater decrease in NT-pro BNP levels at 6 months after initial optimization appointment?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic change</measure>
    <time_frame>6 months</time_frame>
    <description>5. Do patients on the streamlined protocol have a greater reduction in symptoms at 6 months after the initial optimization appointment? Use of the Kansas City Cardiomyopathy Questionaire score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death and worsening heart failure</measure>
    <time_frame>6 months</time_frame>
    <description>Do patients on the streamlined protocol have a lower incidence of the composite endpoint of cardiovascular death and worsening heart failure (defined as hospitalization or an urgent visit resulting in intravenous therapy for heart failure)?</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: Standard Arm&#xD;
Both the current the European society of cardiology guidelines and National Institute of Health and Care Excellence currently advise that chronic stable heart failure patients with severely impaired left ventricular systolic function should initially be optimized as follows:&#xD;
Visit 1: ACEi/ARB and Low Betablocker commenced Visit 2: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 3: ACEi/ARB up-titrated; (Beta Blocker up-titrated) Visit 4: Switch ACEi/ARB to Entresto 100mg Visit 5: Modify Entresto dose to 200mg Visit 6: MRA Added Visit 7: MRA up-titrated Visit 8: SGLT2i started</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Streamlined protocol arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are optimized according to the accelerated protocol adapted from and based on the principles proposed by Prof McMurray and Prof Packer (Circulation 2021;143:875-877)&#xD;
Visit 1: Low Dose Beta Blocker started, SGLT2i started + Entresto 100 mg bd started&#xD;
Visit 2: MRA Added if renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)&#xD;
Visit 3: MRA up-titrated if BP and renal function and potassium levels permit (Betablocker increased if BP and pulse rate permit)&#xD;
Visit 4+: Betablocker increased if BP and pulse rate permit. Further visits may be required to facilitate a gentle up-titration of betablockers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Streamlined protocol</intervention_name>
    <description>A streamlined drug protocol for optimizing heart failure medication</description>
    <arm_group_label>Streamlined protocol arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Protocol</intervention_name>
    <description>Current standard optimization protocol as per NICE and ESC</description>
    <arm_group_label>Standard Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ejection fraction of less than 35%&#xD;
&#xD;
          2. Increased NT-pro BNP levels &gt; 600 pg per milliliter or â‰¥400 pg per milliliter if they&#xD;
             had been hospitalized for heart failure within the previous 12 months.&#xD;
&#xD;
        Patients with atrial fibrillation or atrial flutter on baseline electrocardiography were&#xD;
        required to have an NT-proBNP level of at least 900 pg per milliliter, regardless of their&#xD;
        history of hospitalization for heart failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Systolic BP of less than 100 mmHg on 2 consecutive measurements 2. eGFR less than 30&#xD;
        ml/min/1.73m2 3. Type 1 diabetes mellitus 4. Cognitive impairment that in the opinion of&#xD;
        the investigator may lead the patient to be unable to understand and/or comply with the&#xD;
        study medications, procedures and/or follow-up 5. Uncorrected primary valvular disease 6.&#xD;
        Active malignancy treatment at time of visit 1 7. Women of child-bearing potential who are&#xD;
        not willing to use a medically accepted method of contraception that is reliable in the&#xD;
        judgement of the investigator 8. Women who are pregnant or breastfeeding&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf M Duehmke, BSc MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rudolf M Duehmke, BSc MBBS PhD</last_name>
    <phone>+441553613613</phone>
    <email>rudolf.duehmke@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital King's Lynn</name>
      <address>
        <city>King's Lynn</city>
        <state>Norfolk</state>
        <zip>PE30 4ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medication Sequencing</keyword>
  <keyword>Optimization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

